Related Experiment Videos
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Investigational New Drugs
|November 1, 1990
Abstract:
Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.
Insights
Didemnin B showed minimal effectiveness in treating advanced renal cell cancer, with only one partial response observed. The drug also caused significant allergic reactions, including anaphylaxis, in patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced renal cell carcinoma (RCC) presents a significant clinical challenge.
- Exploring novel therapeutic agents is crucial for improving patient outcomes in advanced RCC.
Purpose of the Study:
- To evaluate the efficacy and safety of Didemnin B in patients with advanced renal cell carcinoma.
Main Methods:
- A clinical trial involving 23 patients with advanced RCC treated with Didemnin B.
- Efficacy assessed by response rates in 21 evaluable patients.
- Adverse events, including allergic reactions, were closely monitored.
Main Results:
- A single partial response (5% response rate) was observed in 21 evaluable patients.
- Four patients experienced allergic reactions, with one case of anaphylaxis.
Conclusions:
- Didemnin B demonstrated limited efficacy in advanced renal cell carcinoma.
- The incidence of severe allergic reactions necessitates caution.
- Didemnin B is not recommended for the treatment of renal cell carcinoma based on these findings.